These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 33408020)
21. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. Mori N; Katayama M; Nukaga S J Microbiol Immunol Infect; 2021 Feb; 54(1):109-112. PubMed ID: 33054978 [TBL] [Abstract][Full Text] [Related]
22. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874 [TBL] [Abstract][Full Text] [Related]
23. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y Clin Microbiol Infect; 2021 Jan; 27(1):138-140. PubMed ID: 33080383 [No Abstract] [Full Text] [Related]
24. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann. Gautret P; Hoang VT; Colson P; Raoult D Int J Antimicrob Agents; 2021 Mar; 57(3):106306. PubMed ID: 33596459 [No Abstract] [Full Text] [Related]
25. Revisiting the cardiovascular risk of hydroxychloroquine in RA. Pers YM; Padern G Nat Rev Rheumatol; 2020 Dec; 16(12):671-672. PubMed ID: 32999492 [TBL] [Abstract][Full Text] [Related]
26. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266 [TBL] [Abstract][Full Text] [Related]
27. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Kim AHJ; Sparks JA; Liew JW; Putman MS; Berenbaum F; Duarte-García A; Graef ER; Korsten P; Sattui SE; Sirotich E; Ugarte-Gil MF; Webb K; Grainger R; Ann Intern Med; 2020 Jun; 172(12):819-821. PubMed ID: 32227189 [TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. Kelly M; O'Connor R; Townsend L; Coghlan M; Relihan E; Moriarty M; Carr B; Melanophy G; Doyle C; Bannan C; O'Riordan R; Merry C; Clarke S; Bergin C Br J Clin Pharmacol; 2021 Mar; 87(3):1150-1154. PubMed ID: 32687645 [TBL] [Abstract][Full Text] [Related]
29. Has the door closed on hydroxychloroquine for SARS-COV-2? Paul M Clin Microbiol Infect; 2021 Jan; 27(1):3-5. PubMed ID: 33096242 [No Abstract] [Full Text] [Related]
30. Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment. Seligmann H Int J Antimicrob Agents; 2021 Mar; 57(3):106292. PubMed ID: 33714420 [No Abstract] [Full Text] [Related]
31. Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. Gautret P; Hoang VT; Honoré S; Roussel Y; Million M; Lagier JC; Raoult D Int J Antimicrob Agents; 2021 Jan; 57(1):106241. PubMed ID: 33408031 [No Abstract] [Full Text] [Related]
32. Repurposing antimalarials and other drugs for COVID-19. Schlagenhauf P; Grobusch MP; Maier JD; Gautret P Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925 [No Abstract] [Full Text] [Related]
33. COVID-19 and antimalarials. Have we been doing it wrong all along? Cismaru CA; Cismaru GL; Seyed Nabavi F; Seyed Nabavi M; Berindan-Neagoe I Eur J Pharmacol; 2021 Jan; 891():173694. PubMed ID: 33130275 [TBL] [Abstract][Full Text] [Related]
34. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19. Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194 [TBL] [Abstract][Full Text] [Related]
35. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. Stewart M; Rodriguez-Watson C; Albayrak A; Asubonteng J; Belli A; Brown T; Cho K; Das R; Eldridge E; Gatto N; Gelman A; Gerlovin H; Goldberg SL; Hansen E; Hirsch J; Ho YL; Ip A; Izano M; Jones J; Justice AC; Klesh R; Kuranz S; Lam C; Mao Q; Mataraso S; Mera R; Posner DC; Rassen JA; Siefkas A; Schrag A; Tourassi G; Weckstein A; Wolf F; Bhat A; Winckler S; Sigal EV; Allen J PLoS One; 2021; 16(3):e0248128. PubMed ID: 33730088 [TBL] [Abstract][Full Text] [Related]
36. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. Szendrey M; Guo J; Li W; Yang T; Zhang S J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391 [TBL] [Abstract][Full Text] [Related]
37. Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report. Sisti G; Schiattarella A; Sisti A Acta Biomed; 2020 Jul; 91(4):e2020123. PubMed ID: 33525254 [TBL] [Abstract][Full Text] [Related]
38. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. Saib A; Amara W; Wang P; Cattan S; Dellal A; Regaieg K; Nahon S; Nallet O; Nguyen LS PLoS One; 2021; 16(6):e0252388. PubMed ID: 34106964 [TBL] [Abstract][Full Text] [Related]
39. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. Altulea D; Maassen S; Baranov MV; van den Bogaart G J Mol Cell Biol; 2021 Jul; 13(3):175-184. PubMed ID: 33693723 [TBL] [Abstract][Full Text] [Related]